Dexcom, Inc.
$35.57B- Market cap
- $33.17B
- Debt
- +$3.32B
- Cash
- −$917.70M
Capital structure 91% equity / 9% debt · EV / Revenue 7.63x · EV / EBITDA 26.75x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $33.17B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: DXCM stock price at premium vs FFIV $87.90 current versus $69.16 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FFIV's multiple
Implied fair value · at DXCM's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Premium justified
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DXCM FY 2025 (ended Dec 31, 2025) · FFIV FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 7.63x · EV / EBITDA 26.75x
Capital structure 98% equity / 2% debt · EV / Revenue 6.86x · EV / EBITDA 24.89x
DXCM carries the larger enterprise value at $35.57B against $21.19B; FFIV trades on the lower EV / Revenue multiple (6.86x vs 7.63x); FFIV on the lower EV / EBITDA (24.89x vs 26.75x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DEXCOM, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
F5, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.21x
0.12x
Net debt / EBITDA
Leverage against operating earnings
1.81x
-1.09x
Cash and equivalents
Liquid reserves on the balance sheet
$917.70M
$1.34B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
DXCM vs ABT
Medtronic plc
DXCM vs MDT
BECTON DICKINSON & CO
DXCM vs BDX
AKAMAI TECHNOLOGIES INC
DXCM vs AKAM
Fastly, Inc.
DXCM vs FSLY
Palo Alto Networks Inc
DXCM vs PANW
DIGI INTERNATIONAL INC
DXCM vs DGII
JUNIPER NETWORKS INC
DXCM vs JNPR
VERISIGN INC/CA
DXCM vs VRSN
$3.32B
$419.78M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.